Attached files
| file | filename |
|---|---|
| EX-99.1 - ORAMED PHARMACEUTICALS INC. | v216243_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 28, 2011
_____________________
ORAMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
|
Nevada
(State or other jurisdiction
of incorporation)
|
000-50298
(Commission File Number)
|
98-0376008
(IRS Employer
Identification No.)
|
Hi-Tech Park 2/5 Givat Ram
PO Box 39098
Jerusalem, Israel 91390
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: 972-2-566-0001
_____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 8.01
|
OTHER EVENTS
|
On March 23, 2011, Oramed Pharmaceuticals Inc. issued a press release announcing that it has successfully completed a toxicity study for its flagship oral insulin capsule, ORMD-0801.
A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
|
(d)
|
Exhibits
|
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release dated March 23, 2011.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ORAMED PHARMACEUTICALS INC.
|
|||
|
Dated: March 28, 2011
|
|||
|
By:
|
/s/ Nadav Kidron
|
||
|
Nadav Kidron
|
|||
|
President, CEO and Director
|
|||
Exhibit Index
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release dated March 23, 2011.
|